Laboratory of Signal Transduction, Department of Medical Sciences, Institute of Biomedicine - iBiMED, University of Aveiro, 3810-193, Aveiro, Portugal.
Department of Medical Sciences, Institute of Biomedicine - iBiMED, University of Aveiro, 3810-193, Aveiro, Portugal.
Med Oncol. 2021 Jan 16;38(1):9. doi: 10.1007/s12032-021-01461-6.
Prostate cancer (PCa) is one of the most common cancer types among men. The quantification of prostate-specific antigen used for PCa detection has revealed limited applicability. Thus, it is crucial to identify new minimally invasive biomarkers for PCa. It is believed that the integration of proteomics data from different studies is vital for identifying new biomarkers for PCa, but studies carried out in this regard have few converging results. Using a different approach, this study aimed to unveil molecular features consistently dysregulated in PCa and potential urinary biomarkers for PCa. The novelty of this analysis relies on the comparison of urinary and tissue proteomes from PCa patients and consequent exclusion of kidney and bladder cancer interference. The conducted bioinformatic analysis revealed molecular processes dysregulated in urine from PCa patients that mirror the alterations in prostate tumor tissue. To identify putative urinary biomarkers, proteins previously detected in kidney and bladder tissues were eliminated from the final list of potential urinary biomarkers for PCa. After a detailed analysis, MSMB, KLK3, ITIH4, ITIH2, HPX, GP2, APOA2 and AZU1 proteins stood out as candidate urinary biomarkers for PCa.
前列腺癌（PCa）是男性最常见的癌症类型之一。用于检测 PCa 的前列腺特异性抗原的定量检测显示出其应用的局限性。因此，确定新的微创生物标志物对于 PCa 至关重要。人们认为整合来自不同研究的蛋白质组学数据对于确定新的 PCa 生物标志物至关重要，但在这方面进行的研究很少有趋同的结果。本研究采用不同的方法，旨在揭示 PCa 中持续失调的分子特征和潜在的 PCa 尿液生物标志物。该分析的新颖之处在于比较了 PCa 患者的尿液和组织蛋白质组，并排除了肾脏和膀胱癌的干扰。进行的生物信息学分析揭示了 PCa 患者尿液中失调的分子过程，这些过程反映了前列腺肿瘤组织的改变。为了确定潜在的尿液生物标志物，从最终的潜在 PCa 尿液生物标志物列表中排除了先前在肾脏和膀胱组织中检测到的蛋白质。经过详细分析，MSMB、KLK3、ITIH4、ITIH2、HPX、GP2、APOA2 和 AZU1 蛋白被认为是 PCa 的候选尿液生物标志物。
